Roivant Sciences (ROIV) is back in focus after a cluster of upbeat analyst ratings coincided with progress in its brepocitinib program, along with mixed clinical news from Immunovant’s autoimmune pipeline.

At a share price of US$28.21, Roivant’s recent 90 day share price return of 20.35% and 1 year total shareholder return of 176.84% indicate strong recent momentum as brepocitinib progresses and analyst sentiment remains supportive.

If this kind of move in biotech catches your interest, it can be useful to see what else is gaining attention in the sector through 31 healthcare AI stocks

With the stock up sharply over the past year, analyst price targets still above the current US$28.21 level and an intrinsic value gap implied by some models, the key question is whether Roivant remains undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 15.2% Undervalued

Roivant’s latest fair value estimate of $33.25 sits above the recent $28.21 close, and the widely followed narrative ties that gap directly to clinical execution and settlement cash.

Roivant's late-stage pipeline, with potential approvals expected in the next couple of years, could lead to a projected $10 billion+ peak sales portfolio, significantly impacting earnings as these therapies are commercialized.

Business development activities with negotiations for potential in-licensing of new programs are ongoing, representing opportunities for revenue growth through the expansion of their development-stage clinical pipeline.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that valuation gap? The narrative leans heavily on steep revenue expansion, a sharp margin reset and a premium future earnings multiple. Curious how those moving pieces combine into a single fair value line for Roivant?

Result: Fair Value of $33.25 (UNDERVALUED)

However, this hinges on successful late stage trials and the outcome of LNP litigation, where setbacks could challenge the growth and valuation story that investors are watching.

Another Lens on Valuation

The story so far leans heavily on fair value models that suggest Roivant is 57.8% below an estimated intrinsic value. On a more traditional yardstick like P/B, however, the shares look expensive at 4.7x versus 2.3x for the US Biotechs average. This raises the question of how much optimism is already embedded in the price.

For a closer look at what this pricing gap could mean over time, including how much room there might be for sentiment to shift toward or away from that higher multiple, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between opportunity and risk, this is a moment to look at the numbers yourself and move quickly to shape an informed view with 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Roivant has sharpened your interest, do not stop here. Use the screener to quickly spot other opportunities that could fit your style before the crowd catches on.

• Target potential underpriced opportunities by scanning 58 high quality undervalued stocks that pair solid fundamentals with room for the market to reassess their price.
• Prioritise resilience by reviewing 73 resilient stocks with low risk scores designed to highlight companies with more stable profiles across key risk checks.
• Hunt for less crowded opportunities by checking the screener containing 23 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.